AU2012224954C1 - Semisolid aqueous pharmaceutical composition containing tapentadol - Google Patents

Semisolid aqueous pharmaceutical composition containing tapentadol Download PDF

Info

Publication number
AU2012224954C1
AU2012224954C1 AU2012224954A AU2012224954A AU2012224954C1 AU 2012224954 C1 AU2012224954 C1 AU 2012224954C1 AU 2012224954 A AU2012224954 A AU 2012224954A AU 2012224954 A AU2012224954 A AU 2012224954A AU 2012224954 C1 AU2012224954 C1 AU 2012224954C1
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
tapentadol
composition according
composition
still
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012224954A
Other languages
English (en)
Other versions
AU2012224954B2 (en
AU2012224954A1 (en
Inventor
Roger Carolus Augusta Embrechts
Sabine Karine Katrien Inghelbrecht
Ulrich Reinhold
Marc Schiller
Eva WULSTEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruenenthal GmbH
Original Assignee
Gruenenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal GmbH filed Critical Gruenenthal GmbH
Publication of AU2012224954A1 publication Critical patent/AU2012224954A1/en
Publication of AU2012224954B2 publication Critical patent/AU2012224954B2/en
Priority to AU2017200040A priority Critical patent/AU2017200040B2/en
Application granted granted Critical
Publication of AU2012224954C1 publication Critical patent/AU2012224954C1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AU2012224954A 2011-03-04 2012-03-02 Semisolid aqueous pharmaceutical composition containing tapentadol Ceased AU2012224954C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2017200040A AU2017200040B2 (en) 2011-03-04 2017-01-04 Semisolid aqueous pharmaceutical composition containing tapentadol

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161449329P 2011-03-04 2011-03-04
US61/449,329 2011-03-04
EP11003603 2011-05-03
EP11003603.5 2011-05-03
PCT/EP2012/000906 WO2012119729A1 (en) 2011-03-04 2012-03-02 Semisolid aqueous pharmaceutical composition containing tapentadol

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017200040A Division AU2017200040B2 (en) 2011-03-04 2017-01-04 Semisolid aqueous pharmaceutical composition containing tapentadol

Publications (3)

Publication Number Publication Date
AU2012224954A1 AU2012224954A1 (en) 2013-09-19
AU2012224954B2 AU2012224954B2 (en) 2016-10-20
AU2012224954C1 true AU2012224954C1 (en) 2017-04-06

Family

ID=44652117

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2012224954A Ceased AU2012224954C1 (en) 2011-03-04 2012-03-02 Semisolid aqueous pharmaceutical composition containing tapentadol
AU2017200040A Ceased AU2017200040B2 (en) 2011-03-04 2017-01-04 Semisolid aqueous pharmaceutical composition containing tapentadol

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2017200040A Ceased AU2017200040B2 (en) 2011-03-04 2017-01-04 Semisolid aqueous pharmaceutical composition containing tapentadol

Country Status (24)

Country Link
US (3) US9446008B2 (https=)
EP (3) EP2680834B1 (https=)
JP (3) JP6027549B2 (https=)
KR (2) KR102039320B1 (https=)
CN (1) CN103501774A (https=)
AU (2) AU2012224954C1 (https=)
BR (1) BR112013022556A8 (https=)
CA (1) CA2828637C (https=)
CY (1) CY1119725T1 (https=)
DK (1) DK2680834T3 (https=)
EA (2) EA025194B1 (https=)
ES (2) ES2654407T3 (https=)
HR (1) HRP20171836T1 (https=)
HU (1) HUE037491T2 (https=)
IL (2) IL227826B (https=)
LT (1) LT2680834T (https=)
MX (2) MX374468B (https=)
NO (1) NO2680834T3 (https=)
PL (1) PL2680834T3 (https=)
PT (2) PT2680834T (https=)
RS (1) RS56692B1 (https=)
SI (1) SI2680834T1 (https=)
WO (1) WO2012119729A1 (https=)
ZA (1) ZA201306480B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101946790B1 (ko) 2011-03-04 2019-02-13 그뤼넨탈 게엠베하 경구 투여를 위한 타펜타돌의 수성 약제학적 제형
RS56692B1 (sr) * 2011-03-04 2018-03-30 Gruenenthal Gmbh Polučvrsta vodena farmaceutska kompozicija koja sadrži tapentadol
US9395306B2 (en) 2011-08-05 2016-07-19 Halliburton Energy Services, Inc. Methods for monitoring fluids within or produced from a subterranean formation during acidizing operations using opticoanalytical devices
US8997860B2 (en) 2011-08-05 2015-04-07 Halliburton Energy Services, Inc. Methods for monitoring the formation and transport of a fracturing fluid using opticoanalytical devices
US8619256B1 (en) 2012-09-14 2013-12-31 Halliburton Energy Services, Inc. Systems and methods for monitoring the properties of a fluid cement composition in a flow path
US20140076550A1 (en) 2012-09-14 2014-03-20 Halliburton Energy Services, Inc. Systems and Methods for Detecting Microannulus Formation and Remediation
US9228940B2 (en) 2012-09-14 2016-01-05 Halliburton Energy Services, Inc. Systems, methods, and apparatuses for in situ monitoring of cement fluid compositions and setting processes thereof
WO2015014980A1 (en) * 2013-08-02 2015-02-05 Ratiopharm Gmbh Composition comprising tapentadol in a dissolved form
EP2845625A1 (en) 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
EP3273953B1 (en) 2015-03-27 2019-01-02 Grünenthal GmbH Stable formulation for parenteral administration of tapentadol
CN109996533A (zh) 2016-09-23 2019-07-09 格吕伦塔尔有限公司 用于肠胃外施用他喷他多的稳定制剂
JP2021532112A (ja) * 2018-07-24 2021-11-25 ドクトア・アウグスト・ボルフ・ゲーエムベーハー・ウント・コンパニー・カー・ゲー−アルツナイミツテル 抗コリン性化合物の局所用エマルション
EP3846852A4 (en) 2018-09-07 2022-06-15 R.P. Scherer Technologies, LLC Solid or semisolid lipid based dosage form stabilization through curing and addition of low hlb surfactant(s)
EP3941422A4 (en) 2019-03-18 2023-04-19 Sunstar Americas, Inc. ORAL CARE COMPOSITION

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775678A (en) * 1984-10-01 1988-10-04 Schering Corporation Clotrimazole cream
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
US6183758B1 (en) * 1998-01-29 2001-02-06 Highland Laboratories, Inc. Phytochemicals, nutrients & medication absorption &/or treatment
US6399087B1 (en) 2000-12-20 2002-06-04 Amphastar Pharmaceuticals, Inc. Propofol formulation with enhanced microbial inhibition
DE10109763A1 (de) 2001-02-28 2002-09-05 Gruenenthal Gmbh Pharmazeutische Salze
US20050176790A1 (en) 2001-02-28 2005-08-11 Johannes Bartholomaus Pharmaceutical salts
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
JP2005526079A (ja) 2002-03-15 2005-09-02 サイプレス バイオサイエンス， インコーポレイテッド 内蔵痛症候群を処置するためのｎｅおよび５−ｈｔ再取り込み阻害剤
US20030191187A1 (en) 2002-04-01 2003-10-09 Lee Fang Yu Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same
EP1545477A4 (en) 2002-09-13 2006-11-22 Cydex Inc CAPSULES CONTAINING AQUEOUS FILLING COMPOSITIONS STABILIZED WITH DERIVED CYCLODEXTRIN
US20040180915A1 (en) 2003-03-14 2004-09-16 Xanodyne Pharmacal, Inc. Methadone-containing compositions for parenteral administration and method of use thereof
WO2005112926A1 (en) 2004-05-17 2005-12-01 Pharmacofore, Inc. Compositions and methods for treating or preventing pain
DE602004007905T2 (de) 2004-06-28 2008-05-08 Grünenthal GmbH Kristalline Formen von (-)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochlorid
BRPI0513300B1 (pt) 2004-07-01 2018-11-06 Gruenenthal Gmbh forma farmacêutica oral, protegida frente ao abuso, contendo (1r, 2r)-3-(3-dimetilamino-1-etil-2- metil-lpropil)-fenol
CN101208081A (zh) 2005-04-28 2008-06-25 谢拉奎斯特生物科学有限公司 治疗疼痛的方法和组合物
TWI329334B (en) 2005-12-02 2010-08-21 Chung Shan Inst Of Science Manufacture method of electromagnetic interference layer for the plasma display panel
US20080039405A1 (en) * 2006-04-25 2008-02-14 Croda, Inc. Modification of percutaneous absorption of topically active materials
RU2442576C2 (ru) 2006-04-28 2012-02-20 Грюненталь Гмбх Фармацевтическая комбинация, содержащая 3-(3-диметиламино-1-этил-2-метилпропил)фенол и парацетамол
CN105561311B (zh) 2006-04-28 2019-07-16 格吕伦塔尔有限公司 包含3-(3-二甲基氨基-1-乙基-2-甲基-丙基)-苯酚和nsaid的药物组合物
WO2008012283A1 (en) 2006-07-24 2008-01-31 Janssen Pharmaceutica Nv Preparation of (2r,3r)-3-(3-methoxyphenyl)-n,n,2-trimethylpentanamine
DE102007012165A1 (de) 2007-03-12 2008-09-18 Grünenthal GmbH Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie des Neuropathieschmerzes
EP1985292A1 (en) 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
CN102908339A (zh) * 2007-11-23 2013-02-06 格吕伦塔尔有限公司 他喷他多组合物
KR101616246B1 (ko) 2008-01-25 2016-05-02 그뤼넨탈 게엠베하 약제학적 투여형
BRPI0921725A2 (pt) 2008-10-30 2016-01-05 Grüenthal GmbH formas de dosagem potentes do tapentadol
WO2010100477A2 (en) 2009-03-03 2010-09-10 Shire Llc Amino acid and peptide carbamate prodrugs of tapentadol and uses thereof
US20100272815A1 (en) 2009-04-28 2010-10-28 Actavis Group Ptc Ehf Amorphous form of tapentadol hydrochloride
US20110190267A1 (en) * 2010-01-05 2011-08-04 Shire Pharmaceuticals, Inc. Prodrugs of opioids and uses thereof
EP2552486B1 (en) * 2010-03-30 2020-08-12 Phosphagenics Limited Transdermal delivery patch
GB201006200D0 (en) 2010-04-14 2010-06-02 Ayanda As Composition
US20120270848A1 (en) * 2010-10-22 2012-10-25 Galleon Pharmaceuticals, Inc. Novel Compositions and Therapeutic Methods Using Same
RS56692B1 (sr) 2011-03-04 2018-03-30 Gruenenthal Gmbh Polučvrsta vodena farmaceutska kompozicija koja sadrži tapentadol

Also Published As

Publication number Publication date
EA201600442A1 (ru) 2017-02-28
KR101911362B1 (ko) 2018-10-25
EP3766489A1 (en) 2021-01-20
CA2828637C (en) 2019-06-11
CA2828637A1 (en) 2012-09-13
ES2654407T3 (es) 2018-02-13
ZA201306480B (en) 2014-05-28
IL227826A0 (en) 2013-09-30
US20180133174A1 (en) 2018-05-17
JP6259042B2 (ja) 2018-01-10
JP2014506900A (ja) 2014-03-20
AU2012224954B2 (en) 2016-10-20
SI2680834T1 (en) 2018-01-31
EA033171B1 (ru) 2019-09-30
PL2680834T3 (pl) 2018-03-30
PT3766489T (pt) 2022-04-07
EP3766489B1 (en) 2022-03-16
HRP20171836T1 (hr) 2017-12-29
MX344473B (es) 2016-12-16
DK2680834T3 (en) 2017-12-04
LT2680834T (lt) 2018-01-10
BR112013022556A2 (pt) 2016-12-06
MX2013010100A (es) 2013-10-01
US20160346229A1 (en) 2016-12-01
IL258357A (en) 2018-05-31
EP3290029A1 (en) 2018-03-07
KR20140013020A (ko) 2014-02-04
MX374468B (es) 2025-03-06
IL227826B (en) 2018-04-30
PT2680834T (pt) 2018-01-25
WO2012119729A1 (en) 2012-09-13
ES2910085T3 (es) 2022-05-11
US9446008B2 (en) 2016-09-20
CN103501774A (zh) 2014-01-08
US20120225950A1 (en) 2012-09-06
NO2680834T3 (https=) 2018-03-17
EP3290029B1 (en) 2020-09-02
KR20180116463A (ko) 2018-10-24
JP2017039756A (ja) 2017-02-23
EP2680834B1 (en) 2017-10-18
JP2018065839A (ja) 2018-04-26
EA025194B1 (ru) 2016-11-30
KR102039320B1 (ko) 2019-11-01
EA201300988A1 (ru) 2014-06-30
BR112013022556A8 (pt) 2018-01-16
EP2680834A1 (en) 2014-01-08
HUE037491T2 (hu) 2018-09-28
JP6027549B2 (ja) 2016-11-16
RS56692B1 (sr) 2018-03-30
AU2012224954A1 (en) 2013-09-19
JP6670283B2 (ja) 2020-03-18
AU2017200040B2 (en) 2018-09-06
CY1119725T1 (el) 2018-06-27
AU2017200040A1 (en) 2017-02-02

Similar Documents

Publication Publication Date Title
AU2012224954C1 (en) Semisolid aqueous pharmaceutical composition containing tapentadol
AU2012224952B2 (en) Aqueous pharmaceutical formulation of tapentadol for oral administration
EP2596788A1 (en) Tacrolimus-containing oil-in-water type creamy composition
JP2025085814A (ja) 医薬組成物
JP4770135B2 (ja) 外用剤
HK1250664A1 (en) Semisolid aqueous pharmaceutical composition containing tapentadol
HK1194966A (en) Semisolid aqueous pharmaceutical composition containing tapentadol
HK1194966B (en) Semisolid aqueous pharmaceutical composition containing tapentadol
WO2007086582A1 (ja) ２２－オキサ－１α,２５－ジヒドロキシビタミンＤ3を含有する水中油型乳剤性ローション剤およびそれを用いた皮膚疾患の治療方法
US20190388364A1 (en) Tapentadol as a local anesthetic
JP2014208617A (ja) 医薬組成物
JP2024519493A (ja) 局所ナプロキセン製剤及びそれらの使用
JP2017178843A (ja) 乳化組成物

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 21 DEC 2016

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 21 DEC 2016

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired